Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quant...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2016-78756-P
MODELOS IN VITRO DE EVALUACION BIOFARMACEUTICA: BARRERAS BIO...
85K€
Cerrado
PRE2021-100416
MEDICINA INTERCEPTIVA, DESCUBRIMIENTO DE DIANAS Y REUTILIZAC...
101K€
Cerrado
SAF2009-12768
MODELIZACION Y SIMULACION PARA DISEÑO Y DESARROLLO DE NUEVOS...
109K€
Cerrado
PTQ2018-010262
Investigación de modelos computacionales para la determinaci...
62K€
Cerrado
ERAMET
Ecosystem for rapid adoption of modelling and simulation MET...
4M€
Cerrado
Información proyecto DDMORE
Duración del proyecto: 65 meses
Fecha Inicio: 2011-03-01
Fecha Fin: 2016-08-31
Líder del proyecto
Pfizer RD UK Limited
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
23M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Model based-drug development (MBDD) is accepted as a vital approach in understanding patient risk/benefit and attrition. At the core of MBDD lies Modelling and Simulation (M&S), a technology providing the basis for informed, quantitative decision-making.M&S facilitates the continuous integration of available information related to a drug or disease into constantly-evolving mathematical models capable of describing and predicting the behaviour of studied systems to address the questions researchers, regulators, and public health care bodies face when bringing drugs to patients.The full adoption of MBDD is frustrated by a lack of common tools, languages and ontologies for M&S, which often leads to inefficient reuse of data and duplication of effort by academic, industrial and regulatory stakeholders.The Drug Disease Model Resources (DDMoRe) consortium’s strategy will have standards as its core: a newly developed common definition language for data, models and workflows, along with an ontology based standard for storage and transfer of models and associated metadata.A drug and disease model library will be developed as a public resource. Its flexibility and power will be showcased by the addition of proof of concept” drug and disease models from key therapeutic areas such as diabetes and oncology.An open-source interoperability framework will be the backbone for the integration of M&S applications into seamless, standardized but flexible workflows. Initially, currently-used tools (e.g. NONMEM, WinBUGS, Matlab, R) will be integrated into the framework. From the outset resources will also be dedicated to new application development which will be steered by identified gaps in the M&S software ecosystem.The DDMoRe project’s standards and tools – intended as the gold standard for future collaborative drug and disease M&S - will be supported by comprehensive training and will be made publicly accessible.